Managing the challenge of chemically reactive metabolites in drug development

B. Kevin Park, Alan Boobis, Stephen Clarke, Chris E P Goldring, David T Jones, J. Gerry Kenna, Craig Lambert, Hugh G. Laverty, Dean J. Naisbitt, Sidney Nelson, Deborah A. Nicoll-Griffith, R. Scott Obach, Philip Routledge, Dennis A. Smith, Donald J. Tweedie, Nico Vermeulen, Dominic P. Williams, Ian D. Wilson, Thomas A. Baillie

Research output: Contribution to JournalReview articleAcademicpeer-review


The normal metabolism of drugs can generate metabolites that have intrinsic chemical reactivity towards cellular molecules, and therefore have the potential to alter biological function and initiate serious adverse drug reactions. Here, we present an assessment of the current approaches used for the evaluation of chemically reactive metabolites. We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity. At early stages of drug discovery, iteration between medicinal chemistry and drug metabolism can eliminate perceived reactive metabolite-mediated chemical liabilities without compromising pharmacological activity or the need for extensive safety evaluation beyond standard practices. In the future, reactive metabolite evaluation may also be useful during clinical development for improving clinical risk assessment and risk management. Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chemical stress-mediated adverse reactions in humans. This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.

Original languageEnglish
Pages (from-to)292-306
Number of pages15
JournalNature Reviews Drug Discovery
Issue number4
Publication statusPublished - Apr 2011


Dive into the research topics of 'Managing the challenge of chemically reactive metabolites in drug development'. Together they form a unique fingerprint.

Cite this